AXGT News and Press, Axovant Gene Therapies Ltd.

Sio Gene Therapies (SIOX) has dosed the first patient in the high-dose cohort of Phase 1/2 (Stage 1) study evaluating AXO-AAV-GM1 gene therapy for Type I (infantile) and Type II (late infantile and juvenile onset) GM1 gangliosidosis.High-dose cohort is evaluating a dose of 4.5x1013&...

On-track to report t opline r esults from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to ra...

A pioneering researcher , Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of...

Effective at the open on Friday, November 13, Axovant Gene Therapies (AXGT) will change its name to Sio Gene Therapies. Shares will trade under the ticker (SIOX).In conjunction with the corporate rebranding, the company has established a majority independent board and will redomicile from Ber...

Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 ...

The FDA has signed off on a registrational study evaluating Axovant Gene Therapies' (AXGT) AXO-AAV-GM2 gene therapy for patients with Tay-Sachs disease and Sandhoff disease, two rare inherited disorders characterized by the buildup of certain kinds of fats in the brain and other organs c...

AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseases Represents Axovant’s second IND clearance for a gene therapy program in the last 12 months NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapie...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks fell on Friday, led by the megacap tech names, to wrap up the worst week since March as coronavirus cases surged, U.S. fiscal stimulus...

Gainers: BioLineRx (BLRX) +76%.Marine Petroleum Trust (MARPS) +65%.DASAN Zhone Solutions (DZSI) +25%.Air Industries (AIRI) +21%.Rogers (ROG) +20%.Acadia Healthcare (ACHC) +18%.Tricida (TCDA) +17%.Covanta Holding (CVA) +16%.MoneyGram International (MGI) +14%.Daseke (DSKE) +14%.Losers: ...

Gainers: BioLineRx BLRX +63%, Acadia Healthcare ACHC +19%, Tricida (TCDA) +14%, Cleveland BioLabs (CBLI) +12%, Equillium EQ +4%.Losers: Axovant Gene Therapies (AXGT) -39%, Bellicum Pharmaceuticals (BLCM) -38%, OPKO Health (OPK) -20%,...